A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Trial Profile

A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Jun 2012 Planned number of patients changed from 330 to 450 as reported by European Clinical Trials Database.
    • 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.
    • 16 Feb 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top